Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Aeglea Biothera (NQ: AGLE)
8.050 USD  +0.150 (+1.90%)
Streaming Delayed Price  /  Updated: 11:11 AM EST, Nov 14, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 45,367
Open 7.880
Bid (Size) 8.010 (1)
Ask (Size) 8.080 (4)
Prev. Close 7.900
Today's Range 7.880 - 8.170
52wk Range 3.750 - 12.00
Shares Outstanding 21,858,874
Dividend Yield N/A
Performance
YTD
+49.63%
+49.63%
1 Month
-14.45%
-14.45%
3 Month
-12.12%
-12.12%
6 Month
-24.34%
-24.34%
1 Year
+67.01%
+67.01%
Top News
More News
Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts — New Horizons, Emerging Trends, and
from GlobeNewswire News Releases
Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,... Read More
from GlobeNewswire News Releases
More News
Read More
Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
from GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
from GlobeNewswire News Releases
Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
from GlobeNewswire News Releases
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
from GlobeNewswire News Releases
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
from GlobeNewswire News Releases
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
from GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
from GlobeNewswire News Releases
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
from GlobeNewswire News Releases
Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.